A Randomized, Open Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigators Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Who Are Current or Former Smokers
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Veliparib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 06 Jul 2017 Planned End Date changed from 31 Jul 2017 to 14 May 2018.
- 06 Jul 2017 Planned primary completion date changed from 31 Jul 2017 to 14 May 2018.
- 27 Apr 2017 Planned End Date changed from 1 Jul 2017 to 31 Jul 2017.